Objective
Influenza virus causes a large socioeconomic burden on society, with 70 000 deaths every year in Europe. It is estimated that 1 in 1000 children and elderly every year are hospitalized due to influenza infection. Children, due to high susceptibility and high levels of shedding, are the main source of spread of the virus. Therefore, CDC in 2010 included children as a high priority group for influenza vaccination. Two influenza vaccines are licensed: inactivated (IIV) and live attenuated (LAIV) vaccine. The LAIV was introduced to provide broader protection by additional stimulation of T cell responses. At present the two major obstacles in the widespread use of LAIV are concerns raised over vaccine effectiveness and the lack of immunological correlates of protection. In 2016 the CDC in the US recommended against the use of LAIV due to its poor effectiveness in the 2015/2016 season. However, the same vaccine, in the same season had high effectiveness as assessed by UK and Finland public health authorities. Currently the reason for this discrepancy is not known. This project will take advantage of cohorts of children who have received LAIV provided by both US and UK sponsors, to investigate the immunological basis for the observed variability and to define the role of adaptive immunity by applying the systems biology tools and machine learning algorithms for predictive modelling. Progress in the clinical investigation of children has been hampered by limited methods that could be applied to the small blood volumes, but recent advances in systems biology have opened new opportunities that did not exist before. Tracing the influenza vaccine imprint on immune system, termed FluPRINT by the proposed project will help to identify cellular signatures of vaccine-induced protection in children which is of importance for the development of next generation of influenza vaccines that will be more effective in this target population.
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: https://op.europa.eu/en/web/eu-vocabularies/euroscivoc.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: https://op.europa.eu/en/web/eu-vocabularies/euroscivoc.
- medical and health sciences health sciences public health
- medical and health sciences health sciences infectious diseases RNA viruses influenza
- medical and health sciences basic medicine immunology
- medical and health sciences basic medicine pharmacology and pharmacy pharmaceutical drugs vaccines
- natural sciences computer and information sciences artificial intelligence machine learning
You need to log in or register to use this function
We are sorry... an unexpected error occurred during execution.
You need to be authenticated. Your session might have expired.
Thank you for your feedback. You will soon receive an email to confirm the submission. If you have selected to be notified about the reporting status, you will also be contacted when the reporting status will change.
Programme(s)
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
-
H2020-EU.1.3. - EXCELLENT SCIENCE - Marie Skłodowska-Curie Actions
MAIN PROGRAMME
See all projects funded under this programme -
H2020-EU.1.3.2. - Nurturing excellence by means of cross-border and cross-sector mobility
See all projects funded under this programme
Topic(s)
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Funding Scheme
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
MSCA-IF-GF - Global Fellowships
See all projects funded under this funding scheme
Call for proposal
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
(opens in new window) H2020-MSCA-IF-2017
See all projects funded under this callCoordinator
Net EU financial contribution. The sum of money that the participant receives, deducted by the EU contribution to its linked third party. It considers the distribution of the EU financial contribution between direct beneficiaries of the project and other types of participants, like third-party participants.
OX1 2JD Oxford
United Kingdom
The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.